NexImmune, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.neximmune.com
Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
Phase 1
Not yet recruiting
- Conditions
- Oropharyngeal CancerHuman Papilloma VirusOropharyngeal Cancer, MetastaticHPV-Related Mucosal Head and Neck Squamous Cell CarcinomaRefractory Oropharyngeal Squamous Cell CarcinomaHPV-Related Squamous Cell CarcinomaHead and Neck CancerOropharyngeal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaHead and Neck Cancer Metastatic
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- NexImmune Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05582590
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
Phase 1
Suspended
- Conditions
- Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- NexImmune Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04505813
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Advent Health Medical Group Blood & Marrow Transplant, Orlando, Florida, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
Phase 1
Active, not recruiting
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- NexImmune Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04284228
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Advent Health Medical Group Blood & Marrow Transplant, Orlando, Florida, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
News
No news found